Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.
Nanomedicine of synergistic drug combinations has shown increasing significance in cancer therapy due to its promise in providing superior therapeutic benefits to the current drug combination therapy used in clinical practice. In this article, we will examine the rationale, principles, and advantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of nanocarriers for delivery of a variety of combinations of different classes of anticancer agents including small molecule drugs and biologics, and discuss the challenges and future perspectives of the nanocarrier-based combination therapy. The goal of this review is to provide better understanding of this increasingly important new paradigm of cancer treatment and key considerations for rational design of nanomedicine of synergistic drug combinations for cancer therapy.
Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, Canada M5S 2S2.
Rui Xue
RX
Zhang
Temple University School of Pharmacy, 3304 North Broad Street, Philadelphia, PA 19140, USA.
Ho Lun
HL
Wong
Temple University School of Pharmacy, 3304 North Broad Street, Philadelphia, PA 19140, USA.
Hui Yi
HY
Xue
Temple University School of Pharmacy, 3304 North Broad Street, Philadelphia, PA 19140, USA.
June Young
JY
Eoh
Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, Canada M5S 2S2.
Xiao Yu
XY
Wu
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004337:Drug Carriers / Q000737:chemistry*; D004357:Drug Synergism; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D050997:Nanomedicine / Q000379:methods* / Q000639:trends; D049329:Nanostructures / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics
D004337:Drug Carriers
Cancer therapy; Nanomedicine; Perspectives; Strategies; Synergistic drug combinations